Lab Industry Says PAMA Reimbursement Rates Not Really Market-Based

The US Medicare agency was supposed to peg its Clinical Lab Fee Schedule reimbursement rates for 2018 to market-based prices supplied by labs under the 2014 Protecting Access to Medicare Act. The exercise might have increased payment rates for lab tests, but clinical labs say that the new Medicare rates actually make deep cuts that could disrupt access to laboratory services.